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Abstract: Photodynamic therapy has been described as an effective therapeutic option in selected cases of
anogenital lichen sclerosus that are refractory to first-line treatments. However, procedure-related pain is a lim-
iting factor in patient adherence to treatment. The authors report the case of a 75-year-old woman with highly
symptomatic vulvar lichen sclerosus, successfully treated with photodynamic therapy. An inhaled 50% nitrous
oxide/oxygen premix was administered during sessions, producing a pain-relieving, anxiolytic, and sedative
effect without loss of consciousness. This ready-to-use gas mixture may be a well-tolerated and accepted alter-
native to classical anesthetics in Photodynamic therapy, facilitating patients' adherence to illumination of pain-
prone areas.
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INTRODUCTION
Lichen sclerosus (LS) is a chronic, autoimmune,
inflammatory skin disease of uncertain aetiology.
Vulvar LS is associated with severe discomfort and
morbidity. Several treatment modalities have been
proposed, with the most available evidence for potent
topical corticosteroids. When unresponsive to medical
therapies, photodynamic therapy (PDT) has been
described as a potential alternative, demonstrating
symptomatic benefit in small series studies and case
reports.1 However, pain is still a major limitation to
this technique and an important cause of treatment
discontinuation.
CASE REPORT
A 75-year-old woman presented with a 15-year
history of vulvar lichen sclerosus. She was highly
symptomatic, reporting a persistent burning sensa-
tion, pain, and pruritus worsened during micturition.
Physical examination showed a shiny, ivory, smooth-
surfaced plaque surrounding the vulva, with impor-
tant atrophy causing labial and clitoral resorption, in
addition to narrowing of the introitus. Histopathology
confirmed the diagnosis of LS. Treatment with clobe-
tasol propionate 0.05% ointment and amitriptylin 10
mg/day for 7 months produced little symptomatic
relief. Photodynamic therapy using methyl aminole-
vulinate (MAL) was then instituted. MAL cream was
applied to the entire labia, with an occlusive dressing
for three hours, followed by illumination with red
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light, 630nm wavelength at a light dose of 37 J/cm2
for 8 minutes and 20 seconds, at a distance of 8cm
between the device and the lesion surface. An inhaled
50% nitrous oxide/oxygen premix was administered
using a face mask, yielding conscious sedation and
pain relief during the entire treatment (Figure 1). Gas
flow was controlled by a sensitive demand-valve acti-
vated by the patient’s inspired breath. Three minutes
after the beginning of gas inhalation, PDT was initiat-
ed, subject to preliminary moderate sedation (in
accordance with the Winsconsin Sedation Scale).
Blood pressure, heart rate, oxygen peripheral satura-
tion and sedation score were monitored throughout
the procedure. Sedation was reversed using oxygen
therapy at a flow rate of 5 litres per minute for 5 min-
utes. A total of four PDT sessions were performed.
Treatment between sessions included daily
amitriptylin and emollient. A visual analogue scale
was used to evaluate response to treatment, through a
daily record of the intensity of symptoms (from 0 to
10), including dysuria, pain and pruritus.
Patient compliance during PDT treatments
under conscious sedation was total, with tolerance to
pain, no need for local anaesthesia, and no side effects
to report. Symptomatic relief was reported as early as
one week after the first treatment. Complete and per-
sistent remission of dysuria has been observed ever
since. Pain and pruritus diminished by up to 80%
from baseline after the first two treatments, recurring
10 and 9 weeks later, respectively. However, a long-
lasting response was experienced after the third ses-
sion, with absent to mild pain or pruritus during nine
months, before recurrence and the need for a fourth
treatment (Figure 2). Overall, while clinically
unchanged, symptomatic response has been observed
following each PDT treatment, with longer intervals
between sessions, and great improvement in the
patient’s quality of life.
DISCUSSION
Procedure-related pain is a limiting factor in
patient adherence to PDT. This adverse event exhibits
great interpersonal variation, but is also related to
predisposition factors such as location, extent and
type of lesion, photosensitizer, fluence, irradiance,
and light source. Pain control strategies during PDT
have been studied, but none has proved completely
effective. For instance, topical anesthetics have
proved ineffective in controlling pain during PDT. In
addition, injectable anesthetics, though useful, are
associated with considerable pain when infiltrated in
extensive and pain-prone areas, and lack anxiolytic
effect.2
When inhaled, a ready-to-use medical gas mix-
ture consisting of 50% nitrous oxide and 50% oxygen
produces a pain-relieving, anxiolytic and sedative
effect without loss of consciousness. It is fast-acting, as
the first effects are felt shortly after 4-5 inhalations. It
is also self-regulated and rapidly eliminated from the
body through pulmonary excretion once inhalation
stops, allowing for a quick recovery. This gas premix
has proved safe with minimal, reversible side effects
that include drowsiness, euphoria and nausea.3 It has
been widely used over the past decades in short-term
procedures where analgesia and sedation with rapid
onset and offset, have been sought. While commonly
employed in areas such as dentistry, obstetrics, or
pediatrics, its use in dermatology appears to be mar-
ginal in the literature.4-7 No use in PDT has been
reported so far.
To the authors’ knowledge, this is the first case
reporting the use of inhaled nitrous oxide/oxygen gas
mixture during PDT performed in the genital area. In
the case described, the extension and localization of
LS would hardly enable a non-traumatic perineum
FIGURE 1: Conscious sedation with inhaled 50% nitrous oxide/
oxygen premix during PDT session
FIGURE 2: Dysuria, pain, and pruritus severity score according to
the patient’s own records over time, and its relation to PDT 
sessions. wks, weeks
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illumination, as this is a well-recognized pain-prone
area. Pain control through the use of this gas mixture
facilitated patient adherence to PDT, with no need for
treatment interruptions, and acceptance of subse-
quent sessions.
In conclusion, the use of a 50% nitrous
oxide/oxygen gas premix may be an economic, safe,
well-tolerated and accepted alternative to classical
anesthetics in PDT. Easily administered by a trained
doctor or nurse, either in inpatient or outpatient set-
tings, it is an attractive, potential adjuvant for numer-
ous, painful dermatological procedures. ❑
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